Skip to content
Lower risk Drug recall · FDA · Published June 6, 2023

HF Acquisition Co recalls glycopyrrolate injection due to labeling mix-up

HF Acquisition Co recalls glycopyrrolate injection vials with potential labeling mix-up. This affects specific lot numbers and expiration dates. Consumers should check their product details.

🇺🇸 FDA recall #D-0870-2023DrugHF Acquisition Co ›
Take action

Contact the company

Recalling firmHF Acquisition Co LLC11629 49th Pl W · Mukilteo, WA 98275-4255
✎ GovInfoNow plain-language explainer

HF Acquisition Co is recalling glycopyrrolate injection vials that may have a labeling mix-up. This could lead to confusion about the product's contents, but the recall does not indicate a safety risk to users. Read more at govinfonow.com/recall/33413-hf-acquisition-co-recalls-glycopyrrolate-injection-due-to-labeling-mix.

Source Summary by GovInfoNow · govinfonow.com/recall/33413-hf-acquisition-co-recalls-glycopyrrolate-injection-due-to-labeling-mix · Updated August 17, 2026 · FDA enforcement record: FDA #D-0870-2023

Cite this page

“HF Acquisition Co recalls glycopyrrolate injection due to labeling mix-up.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/33413-hf-acquisition-co-recalls-glycopyrrolate-injection-due-to-labeling-mix. Based on FDA recall #D-0870-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0870-2023%22&limit=1).

HF Acquisition Co LLC voluntarily recalled Glycopyrrolate Injection USP due to a labeling mix-up hazard, according to the FDA on June 6, 2023.

How to tell if you have it

  • Brand: HF Acquisition Co
  • Product: GLYCOPYRROLATE INJECTION, USP 0.2MG/ML, 1mL VIAL
  • NDC: 51662-1487-3
  • Lot #: 2205095.1
  • Exp. Date: 7/31/2024
  • Quantity: 9 boxes of 25 vials
  • Distribution: TX, AZ and CA

The hazard

The recall addresses a labeling mix-up involving the specified injection product. The FDA classified this as a Class III recall.

Context

GovInfoNow's records show HF Acquisition Co LLC has 5 other recalls on record since June 4, 2020. Other recent recalls of similar products include American Health Packaging Buprenorphine Tablets Recall (Aug. 19, 2026), Precision Dose Glycopyrrolate Oral Solution Recall (July 14, 2026), and Wells Pharma fentanyl injectable solution recall (April 1, 2026).

How to tell if you have this one

Check for the lot number 2205095.1 and expiration date 7/31/2024 on the vial. The product is a glycopyrrolate injection vial with NDC 51662-1487-3.

  • Brand
    HF Acquisition Co
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Look for the lot number 2205095.1 and expiration date 7/31/2024 on the vial.

Where it went and when

Where it was distributed

Distributed in 3 states.

Alaska: not listedAKMaine: not listedMEVermont: not listedVTNew Hampshire: not listedNHWashington: not listedWAIdaho: not listedIDMontana: not listedMTNorth Dakota: not listedNDMinnesota: not listedMNIllinois: not listedILWisconsin: not listedWIMichigan: not listedMINew York: not listedNYRhode Island: not listedRIMassachusetts: not listedMAOregon: not listedORNevada: not listedNVWyoming: not listedWYSouth Dakota: not listedSDIowa: not listedIAIndiana: not listedINOhio: not listedOHPennsylvania: not listedPANew Jersey: not listedNJConnecticut: not listedCTCalifornia: yesCAUtah: not listedUTColorado: not listedCONebraska: not listedNEMissouri: not listedMOKentucky: not listedKYWest Virginia: not listedWVVirginia: not listedVAMaryland: not listedMDDelaware: not listedDEArizona: yesAZNew Mexico: not listedNMKansas: not listedKSArkansas: not listedARTennessee: not listedTNNorth Carolina: not listedNCSouth Carolina: not listedSCDistrict of Columbia: not listedDCOklahoma: not listedOKLouisiana: not listedLAMississippi: not listedMSAlabama: not listedALGeorgia: not listedGAHawaii: not listedHITexas: yesTXFlorida: not listedFL

FDA distribution: “Distributed in TX, AZ and CA only” States read from FDA’s own wording; “not listed” means the notice does not name it.

States: Arizona, California, Texas.

Recall timeline

FDA terminated this recall 9 months after the firm started it.

1. Firm started the recall: Jun 6, 202312. FDA classified it Class III: Jun 8, 202323. Published in FDA’s Enforcement Report: Jun 14, 202334. FDA terminated the recall: Feb 27, 2024420232024
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Is this product safe to use?

The recall is due to a labeling mix-up, not a safety risk. The product is safe to use if the correct labeling is confirmed.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0870-2023 (June 6, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0870-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA